Otezla (Apremilast)

Apremilast, the active ingredient in Otezla, is a phosphodiesterase‑4 (PDE‑4) inhibitor presented as a tablet for oral use. It is indicated for the treatment of certain chronic inflammatory skin conditions in adult patients. GNH USA supplies Otezla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Otezla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Otezla is a phosphodiesterase‑4 inhibitor used in the management of inflammatory skin disorders.

- Plaque psoriasis: reduces skin lesions and improves quality of life. - Psoriatic arthritis: alleviates joint pain and swelling while slowing disease progression. - Oral ulcers associated with Behçet’s disease: decreases frequency and severity of ulcer episodes.

Adverse reactions reported with apremilast are generally mild to moderate and reflect its immunomodulatory activity.

Common Side Effects: - Diarrhea: typically transient and resolves with continued therapy. - Nausea: may occur early in treatment. - Headache: often mild and improves over time. - Upper respiratory tract infection: common viral symptoms. - Weight loss: modest reduction observed in some patients. - Insomnia: occasional difficulty falling asleep.

Serious or Rare Side Effects: - Depression or suicidal ideation: monitor mood changes. - Severe allergic reactions: signs include rash, swelling, or breathing difficulty. - Pancreatitis: rare abdominal pain with elevated enzymes. - Severe infections: opportunistic infections in immunocompromised patients. - Hepatotoxicity: abnormal liver function tests. - Cardiovascular events: rare cases of myocardial infarction reported.

When prescribing apremilast, clinicians should consider several safety aspects.

- Pregnancy: limited data; use only if potential benefit outweighs risk. - Breastfeeding: unknown safety; weigh benefits against potential infant exposure. - Renal impairment: dose adjustment may be required in severe dysfunction. - Hepatic impairment: monitor liver enzymes regularly. - History of depression: assess mental health before initiation. - Store at ambient temperature: keep below 25°C, retain original packaging, and protect from moisture.

Apremilast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may lower apremilact levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase exposure, raising side‑effect risk.

Moderate Interactions (Monitor Closely): - Warfarin: may require INR monitoring. - Methotrexate: additive immunosuppressive effect. - Digoxin: potential increase in serum concentrations. - Oral contraceptives: monitor for reduced efficacy. - Antacids containing aluminum or magnesium: may affect absorption.